Ultragenyx Pharmaceutical (RARE) Gross Profit (2018 - 2026)

Ultragenyx Pharmaceutical (RARE) has 9 years of Gross Profit data on file, last reported at $106.0 million in Q1 2026.

• On a quarterly basis, Gross Profit fell 3.64% year-over-year to $106.0 million in Q1 2026; TTM through Mar 2026 was $559.4 million, a 11.49% increase from a year earlier, with the FY2025 full-year figure at $564.0 million, up 16.77% from the prior year.
• Gross Profit for Q1 2026 stood at $106.0 million, down from $177.9 million in the prior quarter.
• Over the last five years, Gross Profit for RARE reached as high as $177.9 million in Q4 2025 and fell as low as $73.8 million in Q1 2022.
• Historically, Gross Profit has averaged $110.4 million across 5 years, with a median of $106.0 million in 2026.
• Across the five-year window, Gross Profit declined 21.62% in 2022 and soared 36.07% in 2024, its largest moves.
• Year by year, Gross Profit stood at $98.0 million in 2022, then advanced by 17.62% to $115.3 million in 2023, then increased by 27.91% to $147.5 million in 2024, then grew by 20.65% to $177.9 million in 2025, then plunged by 40.43% to $106.0 million in 2026.
• Per Business Quant data, the three most recent Gross Profit figures were $106.0 million in Q1 2026, $177.9 million in Q4 2025, and $131.9 million in Q3 2025.